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Abstract
Background: The aim of this open trial was to examine the influence of acute bright light
exposure on anxiety in older and young adults.
Methods: This study was ancillary to a complex 5-day laboratory experiment testing phase-
responses to light at all times of the day. On 3 consecutive days, participants were exposed to
bright light (3,000 lux) for 3 hours. The Spielberger State-Trait Anxiety Inventory (Form Y1) was
administered 5 minutes before and 20 minutes after each treatment. Mean state anxiety before and
after treatment were analyzed by age, sex, and time ANOVA. To avoid floor effects, only
participants with baseline STAI levels of ≥ 25 were included.
Results: A significant anxiolytic effect of bright light was found for the mean data, as well as for
each of the three days. No significant main effect of age, sex, or interaction of these factors with
STAI change were found.
Conclusion:  The results show consistent and significant (albeit modest) anxiolytic effects
following acute bright light exposure in low anxiety adults. Further randomized, controlled trials in
clinically anxious individuals are needed.
Background
Anxiety is the most common mental illness in the US
[1,2]. Moreover, complaints of anxiety are common
among healthy individuals and have been associated with
numerous negative health consequences [3-5], absentee-
ism [6], and decreased work productivity [6,7].
Anxiolytic drugs have limited long-term efficacy. Their
adverse side effects include dependency (for benzodi-
azepine agonists), drowsiness [8], impaired cognition and
memory [8-10], and sexual dysfunction [10,11]. Alterna-
tive or adjuvant treatments for anxiety might be valuable.
Bright light exposure would be a potentially attractive
anxiolytic treatment. The antidepressant effects of bright
light are well-established for winter depression [12,13], as
well as many other types of nonseasonal depression [14-
17]. The common co-morbidity [5,18] and neurochemi-
cal similarity between anxiety and depression (e.g.,
responsiveness to the same drugs) [19] provide rationales
for expecting that bright light might also have substantial
anxiolytic effects.
Although there has been little systematic investigation of
the anxiolytic effect of bright light, there is some experi-
mental support for this effect. For example, in research of
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light treatment for winter depression, anxiety-related
symptoms have been reduced to approximately the same
degree as depressive symptoms [20]. Similar reduction in
anxiety and depression symptoms following light expo-
sure have also been noted in healthy individuals and indi-
viduals with subsynromal SAD [21]. Some evidence
suggests that both anxiolytic and antidepressant effects of
light might be mediated by serotonergic mechanisms
[22]. The primary aim of the present study was to explore
the anxiolytic effect of bright light in a large sample. Sec-
ondary aims were to contrast effects in older (ages 60–75
yrs) vs. young (ages 18–30 yrs) adults and in women vs.
men. The study was ancillary to a complex 5–6 day labo-
ratory protocol, which allowed us to examine this effect
on 3 consecutive days. The sample generally had low lev-
els of depression, which allowed exploration of anxiolytic
effects independent of antidepressant effects of bright
light.
Methods
Older adults ages 60–75 yr (66.6 ± 4.5 yr) and young
adults ages 18–30 yrs (23.4 ± 3.8 yr) were recruited by
word of mouth, referrals, announcements in local media,
and advertising in newspapers, adult fitness centers, and
senior pages. Initial inclusion criteria, based on several
screening questionnaires, required good health and regu-
lar participation in vigorous aerobic exercise. Exclusions
included: (1) having > 1 of the major risk factors for coro-
nary artery disease [23] including family history of early
myocardial infarction, current smoking, hypertension,
history of hypercholesterolemia, and diabetes mellitus;
(2) having any major symptoms or signs of cardiopulmo-
nary disease [23], including chest pain, dizziness or syn-
cope, orthopnea or nocturnal dyspnea, ankle edema,
heart papitations, claudication, serious heart murmur,
and excessive shortness of breath; (3) recent shift-work
(previous 2 months) or travel across multiple time zones
(previous 4 weeks); (4) abnormal sleep-wake schedule;
(5) depression; (6) use of alpha or beta blockers, antihy-
pertensives, or antidepressants; (7) or any health or men-
tal condition that would contraindicate participating in
the rigors of the experiment.
Prior to participation in the study, written informed con-
sent was obtained from each participant, as approved by
the UCSD Institutional Review Board. Included in the
consent was a description that the study would include
assessment of the influence of bright light on mood,
which is the focus of the present report. The research was
conducted in compliance with the Helsinki Declaration.
Once recruited, participants were required to pass a med-
ical interview and further medical screening. Exclusions
included elevations in fasting plasma lipids and glucose,
hypertension, abnormal resting 12-lead EKG, and signs of
heart disease during a physician-supervised treadmill test
to volitional exhaustion. Participants were not given a
psychiatric interview.
Laboratory protocol
The 5–6 day laboratory protocol was designed to examine
the influence of bright light or exercise on the circadian
system. Participants were randomized to bright light or
exercise treatment, but the present report is limited to data
associated with the bright light treatment. Each partici-
pant stayed in a studio-apartment room and followed a 90
minute "ultra-short" sleep wake cycle [24], involving 60
min wake intervals in dim light (< 50 lux) and 30 min
sleep intervals in darkness. This cycle was repeated
around-the-clock throughout the 5-day period. Food and
drink were available ad libitum (excluding caffeine and
alcohol). The protocol included around-the-clock collec-
tion of urinary and saliva samples (at 90 min intervals)
and completion of several visual analogue scales at 4-hr
intervals. Tests of retinal circadian rhythms (e.g., elec-
trooculography, visual threshold) were performed around
the clock on a subset of participants (n = 12). During the
wake periods, participants were free to engage in seden-
tary activities, including watching television, reading,
receiving visitors, etc. Strenuous exercise was prohibited.
Participants completed the Center for Epidemiological
Studies Depression Scale (CESD) [25] on the first and last
days of the laboratory study.
Light treatments
Participants were exposed to 3 hr of bright light (3,000
lux) on 3 consecutive days. The treatment was adminis-
tered via overhead cool-white fluorescent lights which dis-
tributed the light levels evenly throughout the room. The
light was administered at one of 8 randomly assigned
times-of-day or night, but was provided at the same time-
of-day or night across the 3 days for each individual. The
treatments were administered in a phase-response curve
experiment establishing the direction and magnitude of
phase-shift depending upon the time of treatment.
Anxiety assessement
Anxiety was assessed with Spielberger's State-Trait Anxiety
Inventory (STAI; Form Y1, i.e., "how you feel at the
moment") [26] at 5 min before and 20 min following all
three light treatments. The reliability and validity of the
STAI are well established [26]. Participants were given
standardized instructions prior to completing the STAI
questionnaire.
Data analysis
To avoid floor effects, an a priori decision was made to
exclude participants for whom baseline STAI were < 25,
which would be approximately one standard deviation
below population norms [26]. Data were averaged acrossBMC Psychiatry 2007, 7:62 http://www.biomedcentral.com/1471-244X/7/62
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the 3 days of assessment, and analyzed by repeated meas-
ures ANOVA, comparing responses by age group and sex.
In addition, ANOVAs were calculated for each of the 3
individual days of assessment. Normal distribution of the
data was established. Effect size was calculated by sub-
tracting the mean post-light STAI from the mean pre-light
STAI and dividing this difference by the pooled standard
deviation. Since analysis indicated that there was no sig-
nificant influence of time-of-day on baseline STAI levels
or on anxiolytic responses to bright light, data were col-
lapsed across all times of testing in the present report.
Comparison of anxiolytic response between individuals
whose baseline STAI levels were within the range found
for clinical populations (= 48) [26] vs. individuals with
lower STAI levels was made via an independent t-test.
Normal distribution of the data was verified.
Results
The number of participants excluded from analysis due to
low baseline STAI levels was 25. The present analyses
included 79 participants out of a total of 104. Four partic-
ipants had clinical levels of baseline STAI (50.8 ± 0.87)
(though none had formal DSM IV diagnoses of anxiety
disorders), whereas 75 participants had lower levels (31.0
± 0.57).
The older participants (n = 33) were ages 59–75 years
(66.6 ± 4.5 yr) and the young participants (n = 46) were
ages 18–30 yr (23.4 ± 3.8 yr). Both age groups had low
levels of depressed mood (CESD levels [25] of 8.6 ± 1.0
and 6.9 ± 1.0, respectively, for the young and older partic-
ipants). No significant mood difference between age
groups was found in laboratory levels of CES-D.
A significant mean post-treatment reduction in STAI was
found [F(1,78) = 17.92, p < 0.001]. The corresponding
effect size was 0.36 (95% CI: 0.19–0.53). The reduction in
STAI was significantly greater for participants with clinical
levels of STAI (reduction of 12.37 ± 6.880 compared with
those with lower STAI levels (1.8 ± 0.40) [t(1,770 = 4.76,
p <v0.001]. The anxiolytic effect was also observed sepa-
rately for each of the three DAYS (p = 0.04, 0.02, < 0.001,
respectively). The corresponding effect sizes (and 95% CI)
were 0.23 (0.01–0.45), 0.20 (0.02–0.38), and 0.38 (0.22–
0.54), respectively.
There was no significant age or sex effect. STAI data, col-
lapsed across sex and age group are displayed in Figure 1.
Discussion
The results indicate a significant anxiolytic effect of acute
bright light exposure. Moreover, the effect was consistent
for each of the three days. The anxiolytic effect did not
vary significantly by age group or sex of the participants.
The corresponding effect size is considered small [27], but
comparable to other anxiolytic stimuli in low anxious
adults [28,29].
The data are consistent with other research suggesting a
reduction of anxiety symptoms following bright light
treatment of winter depression [20]. A unique aspect of
the present study is that the anxiolytic effects were
observed after acute exposure to bright light, whereas oth-
ers reports had considered effects after 2 or more weeks of
light treatment.
The results are not consistent with a recent study by Goel
and Etwaroo [30], who found no significant effect of acute
bright light treatment on the POMS-tension subscale, but
a significant antidepressant effect was observed. The dis-
crepancy in findings might be attributed to methodologi-
cal differences. Whereas the present study involved 3 hr of
exposure to 3,000 lux light and assessment of anxiety
change at 20 min post-exposure, the Goel and Etwaroo
study examined anxiety changes during exposure to 30
min of 10,000 lux light [30].
There were several noteworthy limitations of the present
study. First, an obvious methodological limitation was
the lack of a control group, which was not possible in this
ancillary open trial. Nonetheless, we do not think that the
observed changes in STAI can be readily attributed to
behavioral artifacts, such as demand characteristics or
expectancy effects. Anecdotally, it seemed that the subjects
viewed completion of the STAI as a small part of a com-
plex study. As much focus was placed on following the
Mean (± SE) state anxiety (STAI-Y1) assessed 5 min before  and 20 min after bright light treatment (3 hr at 3,000 lux)  averaged over three consecutive days Figure 1
Mean (± SE) state anxiety (STAI-Y1) assessed 5 min before 
and 20 min after bright light treatment (3 hr at 3,000 lux) 
averaged over three consecutive days. Data are combined 
across age and sex.
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ultra-short sleep-wake schedule, collection of urine sam-
ples, etc., it seemed that subjects were unaware of the
research hypothesis of this ancillary study. Were demand
or expectancy effects operating, greater anxiolytic effects
might be expected. The STAI changes are likely also not
attributable to experimentally imposed "time-out" from
daily stressors, as the bright light treatment was not
administered until the participants were in the laboratory
for = 30 hr. Nonetheless, controlled, randomized studies
are needed to verify these findings.
A second limitation was the low baseline levels of anxiety
of the participants. As expected, the few high-anxious par-
ticipants had far greater anxiolytic responses than the
other participants. Despite receiving recommended stand-
ardized instructions for completing the STAI, a remarka-
bly high number of participants were excluded from the
analyses due to low baseline STAI levels (< 25). The deci-
sion to exclude these individuals was made a priori. The
reasons for the low baseline STAI levels are unclear. The
participants might have made efforts to complete the STAI
questionnaires in a socially desirable manner. However,
similarly abnormally low values were not observed for the
CES-D data. The lack of inclusion of individuals ages 31–
58 yrs, who tend to have high rates of anxiety, might have
contributed to low baseline levels.
A third limitation was that the high levels of health and
fitness of the participants was not representative of the
population, particularly not that of older individuals.
However, this limitation might have led to an underesti-
mation of the efficacy of bright light, which have been
more clearly demonstrated in less healthy individuals.
Some correlates of health and fitness, such as better psy-
chological health and greater habitual exposure to bright
outdoor light, might have attenuated the anxiolytic effects
of bright light.
A fourth limitation might have been the unique labora-
tory environment for exploring psychological benefits of
bright light, involving prolonged maintenance of the
ultra-short sleep-wake cycle, a moderate degree of sleep
deprivation, low levels of light exposure, etc. However,
despite the rigors of the experiment, it did not appear to
be "stressful". For example there were no changes in pre-
treatment STAI levels between DAYs 1–3. Indeed, many
subjects reported that the experience was calming. As
addressed above, by separating the subjects from their
usual daily stressors, the environment might have resulted
in an underestimation of the anxiolytic effects of bright
light treatment.
That participants had generally had low levels of depres-
sion suggests that the anxiolytic effect of light exposure
was independent of significant antidepressant effects.
Moreover, in post-hoc analysis, we found no significant
correlation of anxiolytic effect with baseline level of
depression (r = 0.043).
Conclusion
Notwithstanding its limitations, the present study pro-
vides provocative data addressing an important, but
neglected area of research. Although anxiety and depres-
sion are the most common mental disorders, far more
research focus has been placed on depression. This limita-
tion is certainly true for bright light treatment. Whereas
the antidepressant effects of bright light have been exam-
ined in dozens of studies, the studies did not focus on
potential anxiolytic effects of bright light. That significant
anxiolytic effects were observed following acute exposure
in low-anxious subjects gives rise to the exciting possibil-
ity that far greater effects of bright light might be observed
following chronic treatment in high-anxious individuals.
Further randomized, controlled experiments are needed.
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